首页> 外文期刊>Palliative medicine >Barriers and enablers to deprescribing in people with a life-limiting disease: A systematic review
【24h】

Barriers and enablers to deprescribing in people with a life-limiting disease: A systematic review

机译:障碍和使能使人们贬低患有寿命疾病的人:系统审查

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Knowing the barriers/enablers to deprescribing in people with a life-limiting disease is crucial for the development of successful deprescribing interventions. These barriers/enablers have been studied, but the available evidence has not been summarized in a systematic review. Aim: To identify the barriers/enablers to deprescribing of medications in people with a life-limiting disease. Design: Systematic review, registered in PROSPERO (CRD42017073693). Data sources: A systematic search of MEDLINE, Embase, Web of Science and CENTRAL was conducted and extended with a hand search. Peer-reviewed, primary studies reporting on barriers/enablers to deprescribing in the context of explicit life-limiting disease were included in this review. Results: A total of 1026 references were checked. Five studies met the criteria and were included in this review. Three types of barriers/enablers were found: organizational, professional and patient (family)-related barriers/enablers. The most prominent enablers were organizational support (e.g. for standardized medication review), involvement of multidisciplinary teams in medication review and the perception of the importance of coming to a joint decision regarding deprescribing, which highlighted the need for interdisciplinary collaboration and involving the patient and his family in the decision-making process. The most important barriers were shortages in staff and the perceived difficulty or resistance of the nursing home resident's family - or the resident himself. Conclusion and implications of key findings: The scarcity of findings in the literature highlights the importance of filling this gap. Further research should focus on deepening the knowledge on these barriers/enablers in order to develop sustainable multifaceted deprescribing interventions in palliative care.
机译:背景:了解障碍/使能器对益处利疾病的人们贬低,对成功贬低干预措施的发展至关重要。这些障碍/推动者已经研究过,但可用的证据尚未在系统审查中总结。目的:识别障碍/使能器以贬低患有寿命疾病的人们的药物。设计:系统评价,在Prospero注册(CRD42017073693)。数据来源:用手搜索进行和扩展科学和中央网络和中央网络的系统搜索。在本次审查中纳入了同行评审,关于屏障/使能在明确的生活限制性疾病上贬值的屏障/使能的初步研究被列入了本综述。结果:检查总共1026个参考文献。五项研究达到了标准,并被列入了本综述。找到了三种类型的障碍/推动者:组织,专业和患者(家庭) - 相关的障碍/推动者。最突出的推动者是组织支持(例如,用于标准化的药物审查),涉及多学科团队在药物审查中,并对关于剥夺剥夺的联合决定的重要性,这突出了对跨学科合作并涉及患者和他的患者的需要家庭在决策过程中。最重要的障碍是工​​作人员的短缺以及护理家庭居民的家庭的感知困难或抵抗 - 或居民自己。结论及其关键发现的影响:文献中发现的稀缺性突出了填补这一差距的重要性。进一步的研究应侧重于深化这些障碍/推动者的知识,以便在姑息治疗中制定可持续的多方面剥夺剥夺干预措施。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号